Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$509.09 USD

509.09
180,132

+2.75 (0.54%)

Updated Nov 4, 2024 11:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.

    Hill-Rom (HRC) Q4 Earnings and Revenues Top, Margins Up

    Hill-Rom (HRC) witnesses strong revenue growth in Q4, driven by a solid momentum in core business, acquisition of Mortara and contribution from product launches.

      CVS Health (CVS) Beats Q3 Earnings Estimates, Updates View

      CVS Health (CVS) witnesses year-over-year growth in revenues on the back of strength in the Pharmacy Services segment in Q3.

        Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline

        Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.

          CONMED (CNMD) Q3 Earnings and Revenues Beat, Margin Down

          CONMED (CNMD) gains from strength in General Surgery business in Q3, driven by strong performances by Advanced Surgical and Endoscopic Technologies.

            Cardinal Health (CAH) Beats on Q1 Earnings, FY18 View Intact

            Solid growth at Medical Segment drove Cardinal Health's (CAH) first-quarter results. Product launches and completion of strategic acquisitions in the quarter are major positives.

              BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Miss

              BioSrip (BIOS) Q3 revenues affected by the company's shift in strategy to focus on core revenue mix, the impact of the Cures Act and contract modifications with UnitedHealthcare.

                Bruker (BRKR) Q3 Earnings & Revenues Beat Estimates, View Up

                Bruker (BRKR) raises 2017 guidance. The year-over-year increase in Q3 revenues encourages.

                  Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates

                  Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.

                    PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance

                    PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.

                      Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated

                      Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.

                        DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3

                        DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.

                          Align Technology (ALGN) Gains on InvisAlign, Competition Rife

                          Align Technology (ALGN) continues to gain from strength in the InvisAlign space.

                            DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet

                            DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.

                              Omnicell's Higher Investments Drive Costs, Competition Rife

                              Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.

                                STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up

                                STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.

                                  Integra Gains on Global Growth, Hurricanes Hamper Business

                                  Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.

                                    Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid

                                    Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.

                                      Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss

                                      Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.

                                        Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down

                                        Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.

                                          Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View

                                          Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.

                                            IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss

                                            IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.

                                              Ecolab (ECL) Beats Earnings & Revenues in Q3, Cuts 2017 View

                                              Despite reporting solid third-quarter results, Ecolab (ECL) slashed its full-year earnings guidance, thanks to the hurricanes and the divestiture of the Equipment Care business segment.

                                                Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates

                                                Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.

                                                  Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3

                                                  Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.